

 Office No. 104 & 105 (1st Floor), Gundecha Industrial Premises
Co-Operative Society Ltd., Akurli Road, Kandivali (East), Mumbai, Maharashtra, 400101

+91-86555 50242

compliance@genpharmasec.com info@genpharmasec.com

www.genpharmasec.com

## April 5, 2023

BSE Limited Compliance Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

BSE Scrip Code: 531592

Dear Sir/Madam,

## Sub : Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ended on March 31, 2023

Please find enclosed herewith the disclosure under Regulation 31(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the financial year ended March 31, 2023 received from Mr. Rajesh Sadhwani, Promoter of the Company on behalf of all the Promoters of the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Genpharmasec Limited (Formerly Known as Generic Pharmasec Limited)

Heta Shah (Company Secretary & Compliance Officer) M. No. : 69749

Encl: As above



## **RAJESH SADHWANI**

Address: 1004, Bldg No. 5, Marina Residence, Palm Jumeirah, Dubai, UAE E-mail id: rajtoranto@gmail.com Mobile no: +971506255806

Date : April 5, 2023

**BSE Limited Compliance Department of Corporate Services,** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Audit Committee Independent Directors, Office 104 & 105, 1st Floor, Gundecha Industrial Premises, Akurli Road, Kandivali (East), Mumbai - 400101

BSE Scrip Code: 531592

Dear Sir/Madam,

## <u>Sub</u>: <u>Declaration under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for Myself and on behalf of the Promoters for the financial year ended on March 31, 2023</u>

In compliance with the provisions of Regulation 31(4) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, myself Rajesh Sadhwani, Promoter of the Company and on behalf of the Promoters of the Genpharmasec Limited, hereby declare that as on March 31, 2023 we hold 16,60,01,000 Equity Shares of Genpharmasec Limited and we have not made any encumbrance of shares, directly or indirectly, during the financial year ended March 31, 2023.

Kindly take the same on record.

For Genpharmasec Limited, (Formerly known as Generic Pharmasec Limited)

demann

Rajesh Sadhwani Promoter (For Myself & on behalf of the Promoters)